1. Home
  2. VBTX vs BEAM Comparison

VBTX vs BEAM Comparison

Compare VBTX & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VBTX
  • BEAM
  • Stock Information
  • Founded
  • VBTX 2009
  • BEAM 2017
  • Country
  • VBTX United States
  • BEAM United States
  • Employees
  • VBTX N/A
  • BEAM N/A
  • Industry
  • VBTX Major Banks
  • BEAM Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • VBTX Finance
  • BEAM Health Care
  • Exchange
  • VBTX Nasdaq
  • BEAM Nasdaq
  • Market Cap
  • VBTX 1.3B
  • BEAM 1.6B
  • IPO Year
  • VBTX 2014
  • BEAM 2020
  • Fundamental
  • Price
  • VBTX $24.30
  • BEAM $16.76
  • Analyst Decision
  • VBTX Buy
  • BEAM Strong Buy
  • Analyst Count
  • VBTX 6
  • BEAM 11
  • Target Price
  • VBTX $30.00
  • BEAM $48.90
  • AVG Volume (30 Days)
  • VBTX 316.5K
  • BEAM 1.8M
  • Earning Date
  • VBTX 07-22-2025
  • BEAM 08-05-2025
  • Dividend Yield
  • VBTX 3.64%
  • BEAM N/A
  • EPS Growth
  • VBTX 18.60
  • BEAM N/A
  • EPS
  • VBTX 2.04
  • BEAM N/A
  • Revenue
  • VBTX $416,460,000.00
  • BEAM $63,578,000.00
  • Revenue This Year
  • VBTX $12.52
  • BEAM N/A
  • Revenue Next Year
  • VBTX $5.50
  • BEAM $8.82
  • P/E Ratio
  • VBTX $11.85
  • BEAM N/A
  • Revenue Growth
  • VBTX 14.03
  • BEAM N/A
  • 52 Week Low
  • VBTX $19.78
  • BEAM $13.53
  • 52 Week High
  • VBTX $31.62
  • BEAM $35.25
  • Technical
  • Relative Strength Index (RSI)
  • VBTX 49.10
  • BEAM 44.29
  • Support Level
  • VBTX $23.95
  • BEAM $16.18
  • Resistance Level
  • VBTX $25.66
  • BEAM $18.33
  • Average True Range (ATR)
  • VBTX 0.47
  • BEAM 1.10
  • MACD
  • VBTX -0.09
  • BEAM 0.00
  • Stochastic Oscillator
  • VBTX 28.80
  • BEAM 28.65

About VBTX Veritex Holdings Inc.

Veritex Holdings Inc is engaged in the provision of commercial banking products and services to small to medium-sized businesses and professionals. The bank provides a range of banking services to individual and corporate customers, which include commercial and retail lending, and the acceptance of checking and savings deposits. It offers a suite of online banking solutions, including access to account balances, online transfers, online bill payment and electronic delivery of customer statements, as well as automated teller machines, and banking by telephone, mail and personal appointment. The company's primary sources of revenue are derived from interest and dividends earned on loans, debt and equity securities and other financial instruments.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Share on Social Networks: